Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and ABVD for Hodgkin's Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Hodgkin's disease patients who relapse after radiation therapy alone and previously untreated patients with stage II bulky, III and IV who are eligible for ABVD.~2. Must have histologically proven diagnosis of Hodgkin's disease (Nodular sclerosis or mixed cellularity).~3. Must have bidimensionally measurable disease.~4. Must sign a consent form.~5. Must be older than 16 years of age.~6. Must have adequate bone marrow reserve (ANC \> 1,000/microL, Platelet \> 100,000/microL~7. Left Ventricular Ejection Fraction (LVEF) \>/= 50% by multigated acquisition (MUGA) scan or echocardiogram.~8. Serum creatinine \< 2 mg/dl, serum bilirubin \< 2 mg/dl~Exclusion Criteria:~1. HIV positive.~2. Pregnant women and women of child bearing age who are not practicing adequate contraception.~3. Prior chemotherapy.~4. Severe pulmonary disease including Chronic obstructive pulmonary disease (COPD) and asthma.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab + ABVD Chemotherapy (Type: EXPERIMENTAL): Rituximab 375 mg/m\^2 by vein (IV) over 3 to 8 hours weekly for 6 weeks in a row. ABVD Chemo: Adriamycin 25 mg/m\^2 IV, Bleomycin 10 U/m\^2 IV, Vinblastine 6 mg/m\^2 IV, DTIC 375 mg/m\^2 IV. Each but Rituximab over 3 hours every other week for a total of 12 treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).